Newsroom

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), een bedrijf in de commerciële fase dat zich bezighoudt met het onderzoek naar en de ontwikkeling van geneesmiddelen voor de behandeling van ernstige endocrinologische, oncologische, metabole en neurologische aandoeningen door de werking van het hormoon cortisol te beïnvloeden, heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau h...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), un'azienda di fase commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie endocrine, oncologiche, metaboliche e neurologiche attraverso la modulazione degli effetti dell'ormone cortisolo, oggi ha annunciato che il Comitato per i Medicinali per Uso Umano (CHMP) dell’Agenzia europea per i medicinali (EMA) ha raccomandato l'approvazione da parte della Commissione...

REDWOOD CITY, California--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), una empresa de fase comercial dedicada al descubrimiento y el desarrollo de medicamentos para el tratamiento de trastornos endocrinológicos, oncológicos, metabólicos y neurológicos graves mediante la modulación de los efectos de la hormona cortisol, anunció hoy que el Comité de Medicamentos de Uso Humano (CMUH) de la Agencia Europea de Medicamentos recomendó que la Comisión Europea apruebe relacorilant,...

REDWOOD CITY, Kalif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) ist ein Unternehmen in der kommerziellen Phase, das sich mit der Erforschung und Entwicklung von Medikamenten zur Behandlung schwerer endokrinologischer, onkologischer, metabolischer und neurologischer Erkrankungen durch Modulation der Wirkung des Hormons Cortisol befasst. Es gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur der Europäischen Kommission (E...

REDWOOD CITY, Californie--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ : CORT), société au stade commercial spécialisée dans la découverte et le développement de médicaments qui modulent les effets du cortisol, destinés à traiter des maladies graves d'ordre endocrinologique, oncologique, métabolique et neurologique. La société a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments (EMA) a recommandé à la Commission européen...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned a Performance Assessment (assessment) of PA-2 (Excellent) to Gridiron Insurance Underwriters, Inc. (Gridiron) (Plantation, FL) and Signature Specialty, LP (Signature) (Plantation, FL). Signature is a wholly owned subsidiary of Gridiron. The outlook assigned to the assessment is stable.The assessment reflects Gridiron’s exceptional underwriting capabilities, excellent governance and internal controls, strong financial condition, excellent organ...

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against DICK’S Sporting Goods, Inc. (DICK’S) (NYSE: DKS) on behalf of those who purchased or acquired DICK’S common stock between September 8, 2025 and August 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Pennsylvania an...

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against AST SpaceMobile, Inc. (AST) (NASDAQ: ASTS) on behalf of those who purchased or acquired AST securities between March 4, 2025 and July 15, 2026, inclusive. The lawsuit is filed in the United States District Court for the Western District of Texas and is captioned Hunter v....

SHANGHAI--(BUSINESS WIRE)--Recently, LongHu, the century-old brand under Shanghai Zhonghua Pharmaceutical Co., Ltd., joined forces with Eastday to launch a brand revitalization initiative aimed at bringing new vitality to the time-honored Chinese brand through cross-industry collaborations, creative content and innovative consumer experiences. The initiative began at a coffee culture festival, where LongHu attracted widespread attention with its unconventional “LongHu Medicated Oil Coffee.” The...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baidu, Inc. (“Baidu” or the “Company”) (NASDAQ: BIDU) securities between November 18, 2025 and August 17, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR BAIDU, INC. INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIM...